Say Goodbye to Your Smartphone
According to Microsoft engineer Alex Kipman, “Smartphones are yesterday's news. The phone is already dead. People just haven't realized.”

And it’s all thanks to the device inside this black box…
Click here to see it in action.
David F. Novack, insider at Dynavax Technologies
David F. Novack Insider Alerts

Get notified the next time David F. Novack buys or sells Dynavax Technologies stock. Enter your email address below to get our daily insider buying and selling report.

David F. Novack Insider Information

Mr. Novack joined Dynavax in 2013, and currently serves as President and Chief Operating Officer. Previously, Mr. Novack served as Senior Vice President of Operations where he led the company’s technical operations, supply chain, and quality teams through FDA approval, launch and commercialization of HEPLISAV-B. Mr. Novack has more than 30 years of relevant industry experience, with more than 20 years of direct vaccine industry experience. Prior to Dynavax, Mr. Novack was at Novartis where he served in various roles, including Global Head of Technical Operations and Supply Chain for Diagnostics, and Global Head of Manufacturing Strategy for Vaccines. Prior to Novartis, Mr. Novack held management positions at MedImmune and Lederle Laboratories (now Pfizer). Mr. Novack received a B.S. in Biology from the State University of New York at Albany, and an M.B.A. from Columbia University.

What is David F. Novack's net worth?

The estimated net worth of David F. Novack is at least $1.75 million as of April 1st, 2021. Mr. Novack owns 137,399 shares of Dynavax Technologies stock worth more than $1,749,089 as of January 20th. This net worth evaluation does not reflect any other assets that Mr. Novack may own. Learn More.

What is David F. Novack's salary?

As the COO of Dynavax Technologies Co., Mr. Novack earned a total compensation package of $1,512,640.00 in 2020. Mr. Novack earned a salary of $495,000.00, stock awards of $189,700.00, options awards of $523,742.00, non-equity compensation of $302,198.00, and other compensation of $2,000.00.

How do I contact David F. Novack?

The corporate mailing address for Mr. Novack and other Dynavax Technologies executives is 2100 Powell Street Suite 900, Emeryville CA, 94608. Dynavax Technologies can also be reached via phone at (510) 848-5100 and via email at [email protected]

Has David F. Novack been buying or selling shares of Dynavax Technologies?

David F. Novack has not been actively trading shares of Dynavax Technologies during the past quarter. Most recently, David F. Novack sold 20,000 shares of the business's stock in a transaction on Monday, November 1st. The shares were sold at an average price of $20.12, for a transaction totalling $402,400.00.

Who are Dynavax Technologies' active insiders?

Dynavax Technologies' insider roster includes Justin Burgess (Insider), Andrew Hack (Director), Robert Janssen (SVP), and David Novack (COO).

Are insiders buying or selling shares of Dynavax Technologies?

In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 4,471,226 shares worth more than $59,571,522.14. The most recent insider tranaction occured on November, 1st when COO David F Novack sold 20,000 shares worth more than $402,400.00. Insiders at Dynavax Technologies own 11.8 % of the company.

Information on this page was last updated on 11/1/2021.

David F. Novack Insider Trading History at Dynavax Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2021Sell20,000$20.12$402,400.00View SEC Filing Icon  
10/7/2021Sell3,000$18.00$54,000.00View SEC Filing Icon  
10/1/2021Sell17,000$18.23$309,910.00View SEC Filing Icon  
8/24/2021Sell10,000$14.00$140,000.00View SEC Filing Icon  
4/1/2021Sell20,000$9.92$198,400.00137,399View SEC Filing Icon  
3/15/2018Sell16,109$16.30$262,576.70View SEC Filing Icon  
3/13/2018Sell34,214$16.52$565,215.2821,613View SEC Filing Icon  
3/9/2018Sell2,121$17.97$38,114.3777,192View SEC Filing Icon  
See Full Table

David F. Novack Buying and Selling Activity at Dynavax Technologies

This chart shows David F Novack's buying and selling at Dynavax Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dynavax Technologies Company Overview

Dynavax Technologies logo
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
Read More

Today's Range

Now: $12.73
Low: $12.64
High: $13.27

50 Day Range

MA: $14.61
Low: $12.61
High: $17.16

2 Week Range

Now: $12.73
Low: $4.93
High: $21.39

Volume

1,575,912 shs

Average Volume

1,811,022 shs

Market Capitalization

$1.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35
5 Free Wealth Stock Picks
5 free stock picks that could set you up for a fresh new start in 2022.
Learn More.